Kerala HC: Online Publication of Interim Orders is Not Valid Service for Contempt Proceedings || MP High Court: Criminal Record Alone Doesn't Attract Organised Crime Charge under BNS || Allahabad HC: Insurance Company Cannot Challenge Welfare Scheme Compensation Through Writ || Supreme Court Proposes Denying Fuel to Vehicles Without Valid Insurance || Supreme Court: Media Can Report Court Proceedings Without Sharing Audio or Video Clips || Supreme Court: Acquits Murder Convict Jailed for 22 Years, Points to Criminal Justice System Failure || Supreme Court Directs Centre to Issue Environmental Compensation Norms under SWM Rules 2026 || Supreme Court: Employee Who Accepts Resignation Benefits Cannot Later Challenge its Acceptance || Supreme Court: Breach of Contract is Not Cheating Unless Fraud Existed From the Outset || Supreme Court: Specific Performance of an Agreement to Sell May be Denied After a Long Delay

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :